Levi Strauss Raises 2026 Outlook After Q2 Earnings Beat, Shares Drop Despite Strong Results 
Netflix, Disney, YouTube Eye FIFA World Cup TV Rights in Multi-Billion Dollar Battle 
Sino Biopharm Stock Rises After AstraZeneca Licensing Deal, GSK Partnership Expansion 
Fast Retailing Raises Full-Year Forecast After Uniqlo Owner Beats Q3 Profit Estimates 
Apple Tests China's CXMT Memory Chips as DRAM Maker Gains Global Market Share 
Nvidia Invests $500M in Firmus Technologies Ahead of Planned ASX IPO 
OpenAI GPT-5.6 Set for Wider Release After U.S. Commerce Approval, Report Says 
Zhipu AI Raises HK$31.37 Billion in Discounted Share Sale to Accelerate AI Growth 
Bain Capital Exits Kioxia After AI-Fueled Valuation Surge 
SK Hynix’s $28 Billion U.S. Share Sale Draws Massive Demand Amid AI Chip Boom 
Morgan Stanley Names Marks & Spencer Top European Retail Pick, Sees Strong Upside 
Japan Regional Bank Stocks Drop After Zentoshin Bankruptcy Sparks Credit Risk Concerns 
Telenor to Buy Controlling Stake in Bahnhof in $630 Million Broadband Deal 
Chinese Chip Stocks Jump as Apple Reportedly Tests CXMT Memory Chips for China Devices 
Oil and LNG Tankers Turn Back as Strait of Hormuz Security Risks Escalate 
Mizuho’s Top U.S. Industrials Stocks: Why Corteva and Stanley Black & Decker Stand Out 
OpenAI Executive Fidji Simo to Step Down Amid Health Challenges Ahead of IPO 
AMES, Iowa, April 30, 2018 -- NewLink Genetics Corporation (NASDAQ:NLNK) announced today that the company will participate in the following investor conferences:
- Deutsche Bank 43rd Annual Health Care Conference on May 9 at 11:20 AM ET in Boston
- Bank of America Merrill Lynch Global Healthcare Conference 2018 on May 16 at 5:15 PM PT (8:15PM ET) in Las Vegas
A live webcast of both conference presentations will be available on the Company’s website at www.newlinkgenetics.com in the “Investors & Media” section under “Events and Presentations.”
About NewLink Genetics Corporation
NewLink Genetics is a late-stage biopharmaceutical company focusing on discovering, developing and commercializing novel immuno-oncology product candidates to improve the lives of patients with cancer. NewLink Genetics' IDO pathway inhibitors are designed to harness multiple components of the immune system to combat cancer. For more information, please visit www.newlinkgenetics.com and follow us on Twitter @NLNKGenetics.
Investor Contact:
Lisa Miller
Director of Investor Relations
NewLink Genetics
515-598-2555
[email protected]
Media Contact:
Sharon Correia
VP, Integrated Communications
LaVoieHealthScience
617-374-8800, ext. 105
[email protected]
